Proactive Investors - Run By Investors For Investors

Anavex Life Sciences doses patients in Phase 2 ANAVEX2-73 Parkinson disease dementia study

The biotech also has clinical programs for the drug for the treatment of Alzheimer’s disease and Rett Syndrome, a rare neurological disorder that occurs mainly in girls
A researcher in a lab
The company has initiated an Alzheimer’s disease trial for ANAVEX2-73

Anavex Life Sciences Corp (NASDAQ:AVXL) told analysts Wednesday that it has started enrolling and dosing patients for its phase two ANAVEX2-73 Parkinson’s disease dementia (PDD) study.

The New York-based biotech’s lead drug candidate ANAVEX 2-73 has already completed Phase 2a clinical trials for the treatment of Alzheimer's disease.

The drug is also in preclinical clinical trials to treat Rett Syndrome, a rare neurological disorder that occurs mainly in girls, epilepsy and Parkinson's disease dementia, a decline in reasoning that develops in many people living with Parkinson’s a year after diagnosis.

READ: Anavex Life Sciences shares rise after FDA gives green light on Phase 2 trial

“We were pleased to report that we have successfully activated 100% of all planned clinical study sites representing 20 clinical trial sites for the Phase 2 ANAVEX2-73 Parkinson disease dementia study,” Anavex Life Sciences CEO Christopher Missling told analysts on a call Wednesday.

“Enrollment and dosing of patients is currently proceeding as planned,” he added.

The biopharma is proceeding with a phase two double-blind, randomized, placebo-controlled, 14-week safety and efficacy trial of ANAVEX2-73 for the treatment of Parkinson’s disease dementia.

Missling said the company had also successfully initiated a novel genomic marker driven later-stage CNS precision medicine trial for Alzheimer’s disease for ANAVEX2-73 entering fiscal 2019.

“The company has successfully activated 75% of all planned clinical study sites representing 9 clinical trial sites for the Phase 2b/3 ANAVEX2-73 Alzheimer disease study,” said Missling indicating that enrollment and dosing of patients was currently proceeding as planned.

Earnings in focus

The biotech logged a net loss for the year of $17.5 million, or $0.39 per share, compared to a net loss of $13.5 million, or $0.33 per share for the comparative year.

The biotech said that it had cash and equivalents of $22.9 million on its books as of September 30, 2018.

Shares of the biotech fell nearly 3.3% to $2.05 Thursday in midday trade on a broad market pullback.

 

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

View full AVXL profile View Profile

Anavex Life Sciences Timeline

Related Articles

skin
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use